INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
Trial details
- Registry ID
- NCT03037164
- Phase
- Phase 3
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted InfectionsNCT03037164 | Cerus Corporation | Phase 3 | Completed | 2026-04-29Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |